



ILARIS (canakinumab)

#### Instructions

Please complete Part A and have your physician complete Part B. This form may not apply to your specific plan. Before completing the Prior Authorization form, check that this medication is on your plan's drug coverage list. Completion and submission is not a guarantee of approval. Any fees related to the completion of this form are the responsibility of the plan member. Drugs in the Prior Authorization Program may be eligible for reimbursement if the patient does not qualify for coverage under a primary plan or a government program. Drugs used for indications not approved by Health Canada may be denied. For Quebec plan members, RAMQ exception drug criteria may apply. The decision for approval versus denial is based on pre-defined clinical criteria, primarily based on Health Canada approved indication(s) and on supporting evidence-based clinical protocols. The plan member will be notified whether their request has been approved or denied. If you've already purchased the drug, please attach your original receipts along with a regular extended health care claim form.

### <u>Part A – Patient</u> Patient Information

Fatient information				
First Name:			Last Name:	
Insurance Carrier N	lame/Number:			
Group Number:			Client ID:	
Date of Birth (YYYY/MM/DD):			Relationship: Employee Spouse Dependent	
Language: English French			Gender: Male Female	
Address:			<u> </u>	
City:		Province:		Postal Code:
Email address:				
Telephone (home):		Telephone (cell):		Telephone (work):
The patient is a from the educat  The patient is a	tional institution confirm	endent (i.e. attending ling full-time status is eover age 18. The patie	enclosed. ent has signed the auth	ull-time). A copy of the enrolment document norization section below that allows Sun Life
Coordination of be	enefits			
Provincial Coverage	You applied for a drug that may be covered under a provincial plan. To find out if you qualify for coverage, speak to your doctor and apply to the province. Show the provincial response letter to your pharmacist when you receive it.			
Primary Coverage	Has the patient applied What is the coverage d	_		Yes No N/A ed *Attach decision letter*





ILARIS (canakinumab)

### **Authorization**

The answers on this form are true. I allow Sun Life to collect, use and disclose my personal information for three reasons. These reasons are plan administration, underwriting coverage and assessing claims. Sun Life may share (meaning collect and disclose) information with healthcare providers, hospitals, clinics, pharmacies, government programs, patient assistance programs, and any other organization with relevant information about me. Sun Life may also share information with insurers or reinsurers, and agents and service providers of Sun Life and the above parties. Sun Life will share my information only when necessary. My consent applies while this plan is in effect.

I agree that a photocopy or electronic version of this authorization is as valid as the original.

Plan Member Signature	Date
Patient Signature (if over 18 years of age)	Date





ILARIS (canakinumab)

### Part B - Prescriber

Please see instructions on page 1 and complete all sections below. <u>Incomplete forms may result in automatic denial</u>. Please do **not** provide genetic test information or results.

SECTION 1 - DRUG F					
ILARIS (canakinuma	ıb)	New request Renewal request*			
DIN(s)	Dose	Administration (ex: oral, IV, etc)	Frequency	Duration	
Site of drug administrati	ion:			•	
Home Physician's office/Private Clinic Private Clinic (within Hospital - no public or government funding)					
Hospital (inpatient) Hospital (outpatient)					
Name of the hospital or	private clinic:				
Address:					
City:	Prov	ince:	Postal code:		
* Please submit proof  SECTION 2 – ELIGIBI	of prior coverage if availa	able			
1. Please indicate if the	he patient satisfies the be	elow criteria:			

EC	ECTION 2 – ELIGIBILITY CRITERIA		
1.	Ple	ase indicate if the patient satisfies the below criteria:	
NII"	<u>TIAL</u>		
INI			
	Ш	The patient is 2 years or older, AND	
		Treatment is prescribed and supervised by a specialist physician experienced in the diagnosis and treatment of Periodic Fever Syndrome and/or Still's Disease, AND	
Γhe	e dru	g is being used as per the Health Canada approved indication for the treatment of:	
		Cryopyrin-Associated Periodic Syndromes (CAPS), OR	
		Tumor Necrosis Factor (TNF) receptor Associated Periodic Syndromes (TRAPS), OR	
		Hyperimmunoglobulin D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) and the patient has documented prior history of $\geq$ 3 febrile acute flares within 6 months when not receiving prophylactic treatment, OR	
		Familial Mediterranean Fever (FMF) and the patient has active disease despite colchicine or has intolerance to effective doses of colchicine, OR	
		Active Systemic Juvenile Idiopathic Arthritis (SJIA) and the patient has failed at least one previous therapy including ACTEMRA (tocilizumab), OR	
		Active adult-onset Still's disease (AOSD), and the patient has inadequate response, documented intolerance or contraindication to treatment with ≥1 nonsteroidal anti-inflammatory drugs (NSAIDs), and systemic corticosteroids, AND	
		The patient is enrolled in the Patient Support Program "XPOSE Program for Ilaris" (if patient is not enrolled, please contact the program at 1-844-279-7673)	





ILARIS (canakinumab)

RENEWAL		
There is documented evidence of continued benefit for improvement), AND	this patient (i.e., clinical response and serologic	
The patient has had no disease relapse or has had a reduction in flares		
OR		
	ovide rationale for prescribing treatment (do not provide	
SECTION 3 - PRESCRIBER INFORMATION		
Physician's Name:		
Address:		
Tel:	Fax:	
License No.:	Specialty:	
Physician Signature:	Date:	

### **SECTION 4 - RESPECTING YOUR PRIVACY**

Our Purpose is to help our Clients achieve lifetime financial security and live healthier lives. We collect, use and disclose your personal information to: develop and deliver the right products and services; enhance your experience and manage our business operations; perform underwriting, administration and claims adjudication; protect against fraud, errors or misrepresentations; tell you about other products and services; and meet legal and security obligations. We collect it directly from you, when you use our products and services, and from other sources. We keep your information confidential and only as long as needed. People who may access it include our employees, distribution partners such as advisors, service providers, reinsurers, or anyone else you authorize. At times, unless we're prohibited, they may be outside your jurisdiction and your information may be subject to local laws. You can always ask for your information and to correct it if needed. In most cases, you have a right to withdraw your consent, but we may not be able to provide the requested product or service. Read our Global Privacy Statement and local policy at <a href="www.sunlife.ca/privacy">www.sunlife.ca/privacy</a> or call us for a copy.

Questions? Please visit www.sunlife.ca or call toll-free 1-800-361-6212 Monday - Friday, 8 a.m. - 8 p.m. ET





ILARIS (canakinumab)

### **SECTION 5 - CONTACT US**

	You can submit all pages of this form through the mysunlife mobile app or mysunlife.ca. Please use 'prior auth' as the
Ш	reference number.

OR

Please fax or mail the completed form to Sun Life Assurance Company of Canada ®

FAX: 1-855-342-9915 Mail:

Sun Life Assurance Company of

Canada

Attention: Claims Dept. PO Box 11658 STN CV Montreal, QC H3C 6C1

Sun Life Assurance Company of

Canada

Attention: Claims Dept. PO Box 2010 STN Waterloo Waterloo, ON N2J 0A6